Portal de Periódicos da CAPES

Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants

2023; Cell Press; Volume: 26; Issue: 3 Linguagem: Inglês

10.1016/j.isci.2023.106124

2589-0042

Camille Chauvin, Laurine Levillayer, Mathilde Roumier, H. Nielly, Claude Roth, Anupama Karnam, Srinivasa Reddy Bonam, A. Bourgarit, C Dubost, Aurore Bousquet, S. Le Burel, R. Mestiri, D. Sène, Joris Galland, Marc Vasse, Matthieu Groh, Mathilde Marchand, Camille Vassord-Dang, Jean‐François Gautier, N. Pham‐Thi, Christiane Verny, Bruno Pitard, Cyril Planchais, Hugo Mouquet, Richard Paúl, Etienne Simon‐Lorière, Jagadeesh Bayry, Laurent Gilardin, Anavaj Sakuntabhai,

Long-Term Effects of COVID-19

Although tocilizumab treatment in severe and critical coronavirus disease 2019 (COVID-19) patients has proven its efficacy at the clinical level, there is little evidence supporting the effect of short-term use of interleukin-6 receptor blocking therapy on the B cell sub-populations and the cross-neutralization of SARS-CoV-2 variants in convalescent COVID-19 patients. We performed immunological profiling of 69 tocilizumab-treated and non-treated convalescent COVID-19 patients in total. We observed that SARS-CoV-2-specific IgG1 titers depended on disease severity but not on tocilizumab treatment. The plasma of both treated and non-treated patients infected with the ancestral variant exhibit strong neutralizing activity against the ancestral virus and the Alpha, Beta, and Delta variants of SARS-CoV-2, whereas the Gamma and Omicron viruses were less sensitive to seroneutralization. Overall, we observed that, despite the clinical benefits of short-term tocilizumab therapy in modifying the cytokine storm associated with COVID-19 infections, there were no modifications in the robustness of B cell and IgG responses to Spike antigens.